3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
5
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Solid Tumors Harboring a BRAF V600 Mutation
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Disease Progression
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Advanced BRAF Mutant Cancers
1
Interventions
Irinotecan
3
5,10-methylenetetrahydrofolic acid
2
tislelizumab
1
spartalizumab
1
repotrectinib
1
pralsetinib
1
palbociclib
1
encorafenib
1
Pemetrexed
1
Levoleucovorin
1
Leucovorin
1
KRN-330
1
Immune Checkpoint Inhibitors
1
Imatinib Mesylate
1
Gemcitabine
1
Flucytosine
1
Everolimus
1
Cisplatin
1
Cetuximab
1
Capecitabine
1
Ascorbic Acid
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Digestive System Neoplasms
×
encorafenib
×
Clear all
NCT05039177
2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2
Completed
101 enrolled